亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?

德诺苏马布 医学 刮除术 冷冻疗法 骨巨细胞瘤 特立帕肽 唑来膦酸 巨细胞瘤 外科 骨质疏松症 巨细胞 内科学 病理 骨矿物
作者
Guido Scoccianti,Francesca Totti,Maurizio Scorianz,Giacomo Giulio Baldi,Giuliana Roselli,Giovanni Beltrami,Alessandro Franchi,Rodolfo Capanna,Domenico Andrea Campanacci
出处
期刊:Clinical Orthopaedics and Related Research [Ovid Technologies (Wolters Kluwer)]
卷期号:476 (9): 1783-1790 被引量:39
标识
DOI:10.1007/s11999.0000000000000104
摘要

Denosumab is a monoclonal RANKL antibody, which was originally introduced for the treatment of osteoporosis and bone metastases from solid tumors, but more recently has been used for treatment of giant cell tumor of bone (GCTB). In GCTB, denosumab has been used as a single agent in patients with inoperable tumors; it also has been used before surgery in some patients with the aim to downstage the tumor to facilitate a joint-preserving procedure (curettage) rather than a resection. However, few studies are available evaluating the benefits and risks of denosumab for the latter indication.(1) Does preoperative treatment with denosumab reduce the risk of local recurrence in patients treated for GCTB? (2) Are there adverse effects of short-term denosumab use before surgery and, if so, what are they?All patients with a diagnosis of GCTB surgically treated at our institution from June 2009 to June 2016 with curettage and cryotherapy were retrospectively evaluated to compare patients treated with curettage alone versus patients treated with curettage after preoperative therapy with denosumab. During that period, we treated 97 patients for GCTB; 30 patients were excluded because they received a resection; 34 patients were excluded because they received curettage without cryotherapy. Of the remaining 33 patients, four were excluded because they received denosumab only after surgery, one because she received zoledronic acid, one because she received a curettage after her refusal of a resection that was the advised procedure, two because they were lost to followup early, and four because they were treated for recurrence rather than a new diagnosis of GCTB. The remaining 21 patients were included. Twelve lesions had been treated with surgery after denosumab and nine with surgery alone. During the study period, we preferentially used denosumab for the more aggressive-looking lesions. After curettage, cryotherapy of the residual bone walls was performed with argon cryoprobes to -150° C after pouring gel into the cavity, and we then used cement (17 patients) or morcellized allograft (four patients). Tumors were Campanacci Grade 3 in eight of 12 patients in the denosumab group and in two of nine patients in the surgery-only group (p = 0.08), but the extent of epiphyseal juxtaarticular bone involvement was not different between the groups with the numbers available. Median followup was 39 months (range, 14-55 months) in the denosumab group and 27 months (range, 18-92 months) in the surgery-only group. We used chart review to record the proportion of patients in each treatment group who had a local recurrence and to tally adverse events.With the numbers available, there was no difference in the proportion of patients experiencing a recurrence (five of 12 in the denosumab group and one of nine in the surgery-only group; p = 0.18). We found no adverse effects associated with denosumab either during or after treatment; specifically, we found no alterations in electrolyte levels, blood count, or liver and renal function parameters. In this small series, no patient has developed osteonecrosis of the jaw.In this small series, use of denosumab before surgery for GCTB appeared to allow the reforming of a bone peripheral rim around the tumor, perhaps facilitating curettage rather than osteoarticular resection in some patients. However, we did not observe a decrease in the risk of local recurrence with the use of denosumab, suggesting that it may not decrease the aggressiveness of the disease; according to our preliminary results, we cannot exclude that the rate of local recurrence could be even higher after curettage in denosumab-treated patients than in nontreated patients, and until or unless larger studies demonstrate such a reduction, primary intralesional surgery without denosumab seems more prudent when curettage is feasible at presentation. We did not observe any adverse effects with denosumab, but we caution readers that this study was underpowered to detect even relatively common complications and relatively large differences in the risk of local recurrence. Future studies should evaluate denosumab prospectively; given the relative rarity of this tumor, we suspect multicenter studies are needed to achieve this.Level III, therapeutic study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lhz完成签到,获得积分20
2秒前
4秒前
ding应助lhz采纳,获得10
10秒前
小崔发布了新的文献求助10
10秒前
40秒前
lhz发布了新的文献求助10
44秒前
科研通AI2S应助小崔采纳,获得10
48秒前
科研通AI2S应助Attaa采纳,获得10
54秒前
ss25给Omni的求助进行了留言
1分钟前
1分钟前
2分钟前
fsy123发布了新的文献求助10
2分钟前
亦久完成签到 ,获得积分10
2分钟前
细心的如天完成签到 ,获得积分10
2分钟前
Omni给Omni的求助进行了留言
2分钟前
fsy123完成签到,获得积分20
3分钟前
CipherSage应助科研通管家采纳,获得10
3分钟前
脆饼同学发布了新的文献求助10
4分钟前
wanci应助温柔的中蓝采纳,获得10
4分钟前
4分钟前
4分钟前
脆饼同学完成签到 ,获得积分20
4分钟前
眼睛大的松鼠完成签到 ,获得积分10
5分钟前
Omni驳回了ss25应助
6分钟前
8分钟前
华仔应助科研通管家采纳,获得10
9分钟前
Wei发布了新的文献求助50
10分钟前
Jack80应助韦老虎采纳,获得200
10分钟前
10分钟前
12分钟前
景惊蛰完成签到,获得积分10
12分钟前
13分钟前
景惊蛰发布了新的文献求助10
13分钟前
直率的青寒完成签到,获得积分10
15分钟前
华仔应助科研通管家采纳,获得10
15分钟前
16分钟前
yi完成签到,获得积分10
16分钟前
风起云涌龙完成签到 ,获得积分0
17分钟前
韦老虎发布了新的文献求助200
17分钟前
韦老虎发布了新的文献求助200
17分钟前
高分求助中
Sraffa and applied economics: are there classical supply curves? 1000
Heun’s Differential Equations 600
《Fundamentals of Power Supply Design》Robert A. Mammano 510
谁能看见前面有梦可想 500
Wind Effects on Structures: An Introduction to Wind Engineering and Wind Forces in Engineering (2nd Edition) 300
Against the Grain: The Vayda Tradition in Human Ecology and Ecological Anthropology 300
High Wire: How China Regulates Big Tech and Governs Its Economy 260
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2249184
求助须知:如何正确求助?哪些是违规求助? 1898395
关于积分的说明 4734137
捐赠科研通 1687597
什么是DOI,文献DOI怎么找? 856267
版权声明 545196
科研通“疑难数据库(出版商)”最低求助积分说明 453165